Allied Market Research

2024

Diagnostic Radiopharmaceuticals Market

Diagnostic Radiopharmaceuticals Market Size, Share, Competitive Landscape and Trend Analysis Report by Molecule Type, by Mode of Use, by End-Uses and by Application : Opportunity Analysis and Industry Forecast, 2023-2032

LS : Other

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

The Diagnostic radiopharmaceuticals market report presents the current market analysis along with a seven-year market forecast. The report offers an extensive study of global Diagnostic radiopharmaceuticals market with detailed analysis of the significant factors affecting the market. The factors studied in the report include market dynamics, key segments, major geographies, leading players, and competitive scenario.

Report Includes:

  • 80+ data tables and self-explanatory graphs

  • An overview of the global market for Diagnostic radiopharmaceuticals market

  • Discussion of drivers, opportunities, and restraints

The report offers size and forecast by analyzing the global Diagnostic radiopharmaceuticals market with diverse segments classified on the basis of by molecule type, by mode of use, by end-uses, by application. Furthermore, it includes the geographical market analysis of these segments. Each segment is researched at global, regional, as well as country levels to gain a comprehensive understanding of the global Diagnostic radiopharmaceuticals market.

The competitive scenario of the global Diagnostic radiopharmaceuticals market is discussed in the report, providing detailed analysis on competitive landscape. The key players operating in the global Diagnostic radiopharmaceuticals market are studied to acknowledge their share, position, and competitive strength in the market. Analysis of these major players is included in the report to assist in providing a detailed understanding of these players in the market. Furthermore, the company profile section provides different data points, including brief company overview, key executives of the company, major growth strategies adopted by the company, recent financials, new initiatives or strategies adopted by company to sustain and enhance their position and share in the global Diagnostic radiopharmaceuticals market, and with other competitors.

Key players analysed in this report are Jubilant Pharma Limited, Lantheus Medical Imaging, Inc., GE Healthcare, Merck KGaA, ASEA Brown Boveri Limited, Bracco Imaging S.p.A., Eczacibasi-Monrol Nuclear Products, Cardinal Health, Inc., Eli Lilly and Company, Novartis AG

Key Questions Addressed By The Report:

  • What are the major applications of the Diagnostic radiopharmaceuticals market? How lucrative is the opportunity for their growth in the developing economies in the next nine years?

  • Which are the major companies in the Diagnostic radiopharmaceuticals market? What are their key strategies to reinforce their market position?

  • What are the leading countries in the Diagnostic radiopharmaceuticals market? What would be the share of North America and Asia-Pacific in this market in the next nine years?

  • Where will all these developments in the Diagnostic radiopharmaceuticals market take the industry in the mid to long term?

Research Methodology:

AMR offers its clients with a detailed study and research based on a broad variety of factual inputs, which mainly include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play a vital role in designing analytic tools and models, tailored as per the requirement of an industry segment.

For this research report, over 5,500 product/service type literatures, annual reports, industry releases, and other such documents of key industry participants have been studied for better market research. In addition, 20 hours of interviews have been conducted, with a wide range of professionals in the market, including upstream and downstream participants. Primary research is comprehensibly supported by extensive secondary research. Further, authentic industry journals, trade associations’ releases, and government websites have also been analyzed to obtain high-value industry insights.

Key Stakeholders

  • Players operating in the market

  • Suppliers

  • Governments Bodies

  • Distributors

  • C-level Executives

  • Venture Capitalists

  • Universities

Diagnostic Radiopharmaceuticals Market Report Highlights

Aspects Details
icon_5
By Molecule Type
  • Thyroxine (Tc-99m)
  • Octreotide (Ga-68)
  • LeukoScan (99m Tc-HMPAO)
  • Dxatast (S-methyl Cysteinate Dimer (scd))
  • Others
icon_6
By Mode of Use
  • Conventional Usage
  • Newer Usage
icon_7
By End-Uses
  • Imaging
  • Monitoring
  • Therapy
icon_8
By Application
  • Cardiovascular and Lymphatic System
  • Musculoskeletal System
  • Endocrine System
  • Oncology
  • Gastrointestinal System
  • Neurological System
  • Urogenital System
icon_9
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
icon_10
Key Market Players

Lantheus Medical Imaging, Novartis AG, Bracco Imaging S.p.A., Eczacibasi-Monrol Nuclear Products, Jubilant Pharma Limited, GE Healthcare, Cardinal Health, Merck KGaA, Eli Lilly and Company, ASEA Brown Boveri Limited

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Diagnostic Radiopharmaceuticals Market

Opportunity Analysis and Industry Forecast, 2023-2032